Loading…
Regression of Subependymal Giant Cell Astrocytoma With Rapamycin in Tuberous Sclerosis Complex
The authors present a 21-year-old woman who has been receiving rapamycin for 5 months for bilateral subependymal giant cell astrocytomas. The patient was started at a dose of 0.2 mg/kg/day. Levels were maintained between 11 and 13 ng/mL. Magnetic resonance imaging of the brain 2½ months after initia...
Saved in:
| Published in: | Journal of child neurology 2008-10, Vol.23 (10), p.1238-1239 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c463t-3cbf394e9a6d888bf1231de2cf7c80e8322dc48d17a4179b57bcf609960af95d3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c463t-3cbf394e9a6d888bf1231de2cf7c80e8322dc48d17a4179b57bcf609960af95d3 |
| container_end_page | 1239 |
| container_issue | 10 |
| container_start_page | 1238 |
| container_title | Journal of child neurology |
| container_volume | 23 |
| creator | Koenig, Mary Kay Butler, Ian J. Northrup, Hope |
| description | The authors present a 21-year-old woman who has been receiving rapamycin for 5 months for bilateral subependymal giant cell astrocytomas. The patient was started at a dose of 0.2 mg/kg/day. Levels were maintained between 11 and 13 ng/mL. Magnetic resonance imaging of the brain 2½ months after initiating rapamycin demonstrated a decrease in size of both astrocytomas (11 to 7.5 mm on the right and 8 to 5 mm on the left). Further studies are needed with prolonged observation to confirm these findings, determine the length of necessary treatment, and evaluate recurrence risk after discontinuation of rapamycin. |
| doi_str_mv | 10.1177/0883073808321764 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3072698</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0883073808321764</sage_id><sourcerecordid>69710995</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-3cbf394e9a6d888bf1231de2cf7c80e8322dc48d17a4179b57bcf609960af95d3</originalsourceid><addsrcrecordid>eNqFUc1LwzAcDaLonN49SU7eqvlom-QiyNApDASdeDOkaTojbVOTVtx_b8aGXyCSQALv_V7y3gPgCKNTjBk7Q5xTxChHnBLM8nQLjDBDPOGE020wWsHJCt8D-yG8IIR4JtAu2MNcZCQTeASe7szCmxCsa6Gr4P1QmM605bJRNZxa1fZwYuoaXoTeO73sXaPgo-2f4Z3qVLPUtoVxz-OUd0OA97qOl2ADnLimq837AdipVB3M4eYcg4ery_nkOpndTm8mF7NEpzntE6qLiorUCJWXnPOiwoTi0hBdMc2Rie5IqVNeYqZSzESRsUJXORIiR6oSWUnH4Hyt2w1FY0pt2t6rWnbeNsovpVNW_kRa-ywX7k3G-EgueBQ42Qh49zqY0MvGBh2tq9ZEZzIXDMf3sn-JBBNMSVxjgNZEHRMJ3lSfv8FIrtqTv9uLI8ffXXwNbOqKhGRNCGph5IsbfBtT_VvwAzk5o_s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21213232</pqid></control><display><type>article</type><title>Regression of Subependymal Giant Cell Astrocytoma With Rapamycin in Tuberous Sclerosis Complex</title><source>SAGE:Jisc Collections:SAGE Journals Read and Publish 2023-2024:2025 extension (reading list)</source><creator>Koenig, Mary Kay ; Butler, Ian J. ; Northrup, Hope</creator><creatorcontrib>Koenig, Mary Kay ; Butler, Ian J. ; Northrup, Hope</creatorcontrib><description>The authors present a 21-year-old woman who has been receiving rapamycin for 5 months for bilateral subependymal giant cell astrocytomas. The patient was started at a dose of 0.2 mg/kg/day. Levels were maintained between 11 and 13 ng/mL. Magnetic resonance imaging of the brain 2½ months after initiating rapamycin demonstrated a decrease in size of both astrocytomas (11 to 7.5 mm on the right and 8 to 5 mm on the left). Further studies are needed with prolonged observation to confirm these findings, determine the length of necessary treatment, and evaluate recurrence risk after discontinuation of rapamycin.</description><identifier>ISSN: 0883-0738</identifier><identifier>EISSN: 1708-8283</identifier><identifier>DOI: 10.1177/0883073808321764</identifier><identifier>PMID: 18952591</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Antibiotics, Antineoplastic - administration & dosage ; Brain - drug effects ; Brain - pathology ; Brain Neoplasms - drug therapy ; Brain Neoplasms - pathology ; Brain Neoplasms - physiopathology ; Dose-Response Relationship, Drug ; Female ; Glioma, Subependymal - drug therapy ; Glioma, Subependymal - pathology ; Glioma, Subependymal - physiopathology ; Humans ; Magnetic Resonance Imaging ; Sirolimus - administration & dosage ; Treatment Outcome ; Tuberous Sclerosis - drug therapy ; Tuberous Sclerosis - pathology ; Tuberous Sclerosis - physiopathology ; Young Adult</subject><ispartof>Journal of child neurology, 2008-10, Vol.23 (10), p.1238-1239</ispartof><rights>2008 Sage Publications 2008</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-3cbf394e9a6d888bf1231de2cf7c80e8322dc48d17a4179b57bcf609960af95d3</citedby><cites>FETCH-LOGICAL-c463t-3cbf394e9a6d888bf1231de2cf7c80e8322dc48d17a4179b57bcf609960af95d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18952591$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koenig, Mary Kay</creatorcontrib><creatorcontrib>Butler, Ian J.</creatorcontrib><creatorcontrib>Northrup, Hope</creatorcontrib><title>Regression of Subependymal Giant Cell Astrocytoma With Rapamycin in Tuberous Sclerosis Complex</title><title>Journal of child neurology</title><addtitle>J Child Neurol</addtitle><description>The authors present a 21-year-old woman who has been receiving rapamycin for 5 months for bilateral subependymal giant cell astrocytomas. The patient was started at a dose of 0.2 mg/kg/day. Levels were maintained between 11 and 13 ng/mL. Magnetic resonance imaging of the brain 2½ months after initiating rapamycin demonstrated a decrease in size of both astrocytomas (11 to 7.5 mm on the right and 8 to 5 mm on the left). Further studies are needed with prolonged observation to confirm these findings, determine the length of necessary treatment, and evaluate recurrence risk after discontinuation of rapamycin.</description><subject>Antibiotics, Antineoplastic - administration & dosage</subject><subject>Brain - drug effects</subject><subject>Brain - pathology</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Brain Neoplasms - pathology</subject><subject>Brain Neoplasms - physiopathology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Glioma, Subependymal - drug therapy</subject><subject>Glioma, Subependymal - pathology</subject><subject>Glioma, Subependymal - physiopathology</subject><subject>Humans</subject><subject>Magnetic Resonance Imaging</subject><subject>Sirolimus - administration & dosage</subject><subject>Treatment Outcome</subject><subject>Tuberous Sclerosis - drug therapy</subject><subject>Tuberous Sclerosis - pathology</subject><subject>Tuberous Sclerosis - physiopathology</subject><subject>Young Adult</subject><issn>0883-0738</issn><issn>1708-8283</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNqFUc1LwzAcDaLonN49SU7eqvlom-QiyNApDASdeDOkaTojbVOTVtx_b8aGXyCSQALv_V7y3gPgCKNTjBk7Q5xTxChHnBLM8nQLjDBDPOGE020wWsHJCt8D-yG8IIR4JtAu2MNcZCQTeASe7szCmxCsa6Gr4P1QmM605bJRNZxa1fZwYuoaXoTeO73sXaPgo-2f4Z3qVLPUtoVxz-OUd0OA97qOl2ADnLimq837AdipVB3M4eYcg4ery_nkOpndTm8mF7NEpzntE6qLiorUCJWXnPOiwoTi0hBdMc2Rie5IqVNeYqZSzESRsUJXORIiR6oSWUnH4Hyt2w1FY0pt2t6rWnbeNsovpVNW_kRa-ywX7k3G-EgueBQ42Qh49zqY0MvGBh2tq9ZEZzIXDMf3sn-JBBNMSVxjgNZEHRMJ3lSfv8FIrtqTv9uLI8ffXXwNbOqKhGRNCGph5IsbfBtT_VvwAzk5o_s</recordid><startdate>20081001</startdate><enddate>20081001</enddate><creator>Koenig, Mary Kay</creator><creator>Butler, Ian J.</creator><creator>Northrup, Hope</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20081001</creationdate><title>Regression of Subependymal Giant Cell Astrocytoma With Rapamycin in Tuberous Sclerosis Complex</title><author>Koenig, Mary Kay ; Butler, Ian J. ; Northrup, Hope</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-3cbf394e9a6d888bf1231de2cf7c80e8322dc48d17a4179b57bcf609960af95d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Antibiotics, Antineoplastic - administration & dosage</topic><topic>Brain - drug effects</topic><topic>Brain - pathology</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Brain Neoplasms - pathology</topic><topic>Brain Neoplasms - physiopathology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Glioma, Subependymal - drug therapy</topic><topic>Glioma, Subependymal - pathology</topic><topic>Glioma, Subependymal - physiopathology</topic><topic>Humans</topic><topic>Magnetic Resonance Imaging</topic><topic>Sirolimus - administration & dosage</topic><topic>Treatment Outcome</topic><topic>Tuberous Sclerosis - drug therapy</topic><topic>Tuberous Sclerosis - pathology</topic><topic>Tuberous Sclerosis - physiopathology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koenig, Mary Kay</creatorcontrib><creatorcontrib>Butler, Ian J.</creatorcontrib><creatorcontrib>Northrup, Hope</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of child neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koenig, Mary Kay</au><au>Butler, Ian J.</au><au>Northrup, Hope</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Regression of Subependymal Giant Cell Astrocytoma With Rapamycin in Tuberous Sclerosis Complex</atitle><jtitle>Journal of child neurology</jtitle><addtitle>J Child Neurol</addtitle><date>2008-10-01</date><risdate>2008</risdate><volume>23</volume><issue>10</issue><spage>1238</spage><epage>1239</epage><pages>1238-1239</pages><issn>0883-0738</issn><eissn>1708-8283</eissn><abstract>The authors present a 21-year-old woman who has been receiving rapamycin for 5 months for bilateral subependymal giant cell astrocytomas. The patient was started at a dose of 0.2 mg/kg/day. Levels were maintained between 11 and 13 ng/mL. Magnetic resonance imaging of the brain 2½ months after initiating rapamycin demonstrated a decrease in size of both astrocytomas (11 to 7.5 mm on the right and 8 to 5 mm on the left). Further studies are needed with prolonged observation to confirm these findings, determine the length of necessary treatment, and evaluate recurrence risk after discontinuation of rapamycin.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>18952591</pmid><doi>10.1177/0883073808321764</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0883-0738 |
| ispartof | Journal of child neurology, 2008-10, Vol.23 (10), p.1238-1239 |
| issn | 0883-0738 1708-8283 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3072698 |
| source | SAGE:Jisc Collections:SAGE Journals Read and Publish 2023-2024:2025 extension (reading list) |
| subjects | Antibiotics, Antineoplastic - administration & dosage Brain - drug effects Brain - pathology Brain Neoplasms - drug therapy Brain Neoplasms - pathology Brain Neoplasms - physiopathology Dose-Response Relationship, Drug Female Glioma, Subependymal - drug therapy Glioma, Subependymal - pathology Glioma, Subependymal - physiopathology Humans Magnetic Resonance Imaging Sirolimus - administration & dosage Treatment Outcome Tuberous Sclerosis - drug therapy Tuberous Sclerosis - pathology Tuberous Sclerosis - physiopathology Young Adult |
| title | Regression of Subependymal Giant Cell Astrocytoma With Rapamycin in Tuberous Sclerosis Complex |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T06%3A58%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Regression%20of%20Subependymal%20Giant%20Cell%20Astrocytoma%20With%20Rapamycin%20in%20Tuberous%20Sclerosis%20Complex&rft.jtitle=Journal%20of%20child%20neurology&rft.au=Koenig,%20Mary%20Kay&rft.date=2008-10-01&rft.volume=23&rft.issue=10&rft.spage=1238&rft.epage=1239&rft.pages=1238-1239&rft.issn=0883-0738&rft.eissn=1708-8283&rft_id=info:doi/10.1177/0883073808321764&rft_dat=%3Cproquest_pubme%3E69710995%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c463t-3cbf394e9a6d888bf1231de2cf7c80e8322dc48d17a4179b57bcf609960af95d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=21213232&rft_id=info:pmid/18952591&rft_sage_id=10.1177_0883073808321764&rfr_iscdi=true |